Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).

CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...

Shaw, Chairperson of Biocon, has urged the government to remove tax on medicines used to treat cancer, chronic illnesses, and ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks ...